Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz. The company's name, derived from the latin novae artes, means 'new skills' and reflects the company's commitment to bringing new healthcare products to patients and physicians worldwide.
Novartis offers a wide range of healthcare products through its Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health divisions.
The company is committed to building sustainable competitive advantage for Novartis through the quality, the capability, and ultimately the performance of its people.
Industry experts have ranked Novartis as a leader for having one of the best combinations of organic growth, pipeline opportunities, and low patent-risk exposure among major companies in the pharmaceuticals industry.
The Novartis Pharmaceuticals Division is a world leader in the discovery, development, manufacture and marketing of prescription medicine. Its goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around the world.
The Pharmaceuticals Division is recognized worldwide for the innovative medicines that Novartis provides to patients, physicians and healthcare organizations.
This growing business develops and markets patent-protected prescription drugs for important health needs. Products are concentrated in major therapeutic areas: Cardiovascular & Metabolism; Oncology & Hematology; Neuroscience; Respiratory; Infectious Diseases, Transplantation & Immunology (IDTI); Ophthalmics, Dermatology, Gastrointestinal, Urinary (ODGU); Arthritis & Bone.
Novartis has received 15 new pharmaceutical product approvals in the US since 2000 - the most of any pharmaceutical company - and the company's current product portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. The product development pipeline involves nearly 140 projects – including potential new products as well as potential new indications or formulations for existing products – in various stages of clinical development.
Our success depends entirely on the creativity, performance, and achievements of our associates at all levels. We value challenge, innovation, collaboration, and learning.
We need people who are capable of anticipating and responding quickly to the dynamic environment and industry we work in.